Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Abstract : There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.
Document type :
Journal articles
Complete list of metadatas

Cited literature [25 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01319327
Contributor : Elizabeth Bernardo <>
Submitted on : Friday, May 20, 2016 - 4:05:23 PM
Last modification on : Thursday, February 7, 2019 - 3:12:18 PM

File

PDFEqu14.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : inserm-01319327, version 1
  • PUBMED : 27172791

Collections

Citation

Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, et al.. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget, Impact journals, 2016. ⟨inserm-01319327⟩

Share

Metrics

Record views

215

Files downloads

159